These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 23189380)
41. Methylphenidate-Induced Raynaud Phenomenon Developed After Increasing Methylphenidate in an Adult With Attention-Deficit Hyperactivity Disorder. Monteerarat Y; Pariwatcharakul P J Clin Psychopharmacol; 2019; 39(2):178-179. PubMed ID: 30811376 [No Abstract] [Full Text] [Related]
42. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. Biederman J J Clin Psychiatry; 2003; 64 Suppl 11():3-8. PubMed ID: 14529323 [TBL] [Abstract][Full Text] [Related]
43. Is There an Effect of Methylphenidate on Thrombocytopenia? Ercan ES; Inci SB; Ipci M J Clin Psychopharmacol; 2017 Jun; 37(3):374. PubMed ID: 28301399 [No Abstract] [Full Text] [Related]
44. The run on Ritalin. Attention deficit disorder and stimulant treatment in the 1990s. Diller LH Hastings Cent Rep; 1996; 26(2):12-8. PubMed ID: 8722521 [No Abstract] [Full Text] [Related]
45. [Methylphenidate. A drug for attention deficit disorders to be used with precaution]. Taéron C Rev Infirm; 2009 Jun; (151):47-9. PubMed ID: 19579855 [No Abstract] [Full Text] [Related]
46. Attention deficit hyperactivity disorder and substance use disorders. Szobot CM; Bukstein O Child Adolesc Psychiatr Clin N Am; 2008 Apr; 17(2):309-23, viii. PubMed ID: 18295148 [TBL] [Abstract][Full Text] [Related]
47. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents. Williams RJ; Goodale LA; Shay-Fiddler MA; Gloster SP; Chang SY Am J Addict; 2004; 13(4):381-9. PubMed ID: 15370936 [TBL] [Abstract][Full Text] [Related]
48. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216 [TBL] [Abstract][Full Text] [Related]
49. OROS-Methylphenidate-Induced Raynaud's Phenomenon: A Dose-Related Side Effect. Bayram Ö; Hergüner S J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):521-2. PubMed ID: 26222712 [No Abstract] [Full Text] [Related]
50. Aptensio XR--another long-acting methylphenidate. Med Lett Drugs Ther; 2015 Jul; 57(1473):101-3. PubMed ID: 26204039 [No Abstract] [Full Text] [Related]
51. [Malnutrition in children with DAMP?]. Andersen LL Ugeskr Laeger; 2009 Mar; 171(10):824. PubMed ID: 19280776 [No Abstract] [Full Text] [Related]
52. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007. Janols LO; Liliemark J; Klintberg K; von Knorring AL Nord J Psychiatry; 2009 Nov; 63(6):508-16. PubMed ID: 19958258 [TBL] [Abstract][Full Text] [Related]
53. Reversible ischaemic neurological deficit associated with short-term methylphenidate medication. Leonhard C; Reif A; Beck M; Jacob C; Lesch KP Int J Neuropsychopharmacol; 2006 Feb; 9(1):129-30. PubMed ID: 16004621 [No Abstract] [Full Text] [Related]
54. Childhood stimulant treatment and risk for later substance abuse. Fischer M; Barkley RA J Clin Psychiatry; 2003; 64 Suppl 11():19-23. PubMed ID: 14529326 [TBL] [Abstract][Full Text] [Related]
55. An update on attention deficit disorder. Harv Ment Health Lett; 2004 May; 20(11):4-7. PubMed ID: 15153391 [No Abstract] [Full Text] [Related]
56. Does stimulant treatment place children at risk for adult substance abuse? A controlled, prospective follow-up study. Mannuzza S; Klein RG; Moulton JL J Child Adolesc Psychopharmacol; 2003; 13(3):273-82. PubMed ID: 14642015 [TBL] [Abstract][Full Text] [Related]
57. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Fone KC; Nutt DJ Curr Opin Pharmacol; 2005 Feb; 5(1):87-93. PubMed ID: 15661631 [TBL] [Abstract][Full Text] [Related]
58. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. Pae CU Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730 [No Abstract] [Full Text] [Related]